| Stage | ELV | % of rev | HCA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $51.4B | 100.00% | $19.8B | 100.00% | ELV ×2.59 |
| Gross profit | $8.0B | 15.57% | $11.3B | 56.77% | HCA +41.2pp |
| Operating income | $2.2B | 4.18% | $3.0B | 14.90% | HCA +10.7pp |
| Pre-tax income | $1.8B | 3.49% | $2.4B | 11.94% | HCA +8.5pp |
| Net income | $1.3B | 2.61% | $1.8B | 9.32% | HCA +6.7pp |
| Stage | ELV | HCA | Gap · A − B |
|---|---|---|---|
| Revenue | $51.4B100.00% | $19.8B100.00% | ELV ×2.59 |
| Gross profit | 15.57%$8.0B | 56.77%$11.3B | HCA +41.2pp |
| Operating income | 4.18%$2.2B | 14.90%$3.0B | HCA +10.7pp |
| Pre-tax income | 3.49%$1.8B | 11.94%$2.4B | HCA +8.5pp |
| Net income |
| 2.61%$1.3B |
| 9.32%$1.8B |
| HCA +6.7pp |
No shared counterparties.